Allarity Therapeutics Files 8-K
Ticker: ALLR · Form: 8-K · Filed: Mar 18, 2025 · CIK: 1860657
Sentiment: neutral
Topics: corporate-filing, financial-reporting
Related Tickers: ALLR
TL;DR
ALLARITY THERAPEUTICS (ALLR) FILED AN 8-K ON 3/18/25 - BASIC CORPORATE INFO UPDATE.
AI Summary
Allarity Therapeutics, Inc. filed an 8-K on March 18, 2025, reporting other events and financial statements. The filing details the company's principal executive offices located at 24 School Street, 2nd Floor, Boston, MA 02108, and its telephone number is 401-426-4664. The report covers events up to March 17, 2025.
Why It Matters
This 8-K filing provides an update on Allarity Therapeutics' corporate activities and financial reporting, which is crucial for investors to stay informed about the company's status.
Risk Assessment
Risk Level: low — This filing is a routine 8-K reporting basic corporate information and financial statements, with no immediate material events disclosed.
Key Players & Entities
- Allarity Therapeutics, Inc. (company) — Registrant
- March 17, 2025 (date) — Earliest event reported
- March 18, 2025 (date) — Date of report
- 24 School Street, 2nd Floor, Boston, MA 02108 (address) — Principal executive offices
- 401-426-4664 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing for Allarity Therapeutics?
The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of March 17, 2025.
When was this 8-K report filed with the SEC?
This 8-K report was filed on March 18, 2025.
Where are Allarity Therapeutics' principal executive offices located?
Allarity Therapeutics' principal executive offices are located at 24 School Street, 2nd Floor, Boston, MA 02108.
What is the telephone number for Allarity Therapeutics?
The telephone number for Allarity Therapeutics is (401) 426-4664.
What is the SEC file number for Allarity Therapeutics?
The SEC file number for Allarity Therapeutics is 001-41160.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 18, 2025 regarding Allarity Therapeutics, Inc. (ALLR).